CoChat

A new method for pharmaceutical compounding and storage of anti-VEGF biologics for intravitreal use in silicone oil-free prefilled plastic syringes

Open access

The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.

Abstract

Intravitreal injections of antibody-based biologics targeting vascular endothelial growth factor (VEGF) are highly effective and have markedly decreased the risk of visual impairment associated with prevalent retinal diseases, such as neovascular age-related macular degeneration and diabetes macular oedema. The diseases are chronic in their nature, and most patients need long-term therapy to suppress disease activity. We previously reported a compounding method for repackaging and storage of aflibercept (Eylea), a commonly used anti-VEGF biologic, in silicone oil-coated plastic syringes without compromising drug stability or activity. In addition to improving safety and time spent per patient, compounding of anti-VEGF biologics enables single-dose vials to be split into multiple syringes, thereby considerably reducing waste and drug expenses. However, symptomatic silicone oil droplets may deposit in the eye’s vitreous body after repetitive injections. To fully avoid this complication, we here report on a novel pharmaceutical compounding method using silicone oil-free syringes and a 33 G × 9 mm Low Dead Space Needle hub injection needle. We evaluate the method for three anti-VEGF biologics commonly used in ophthalmology: aflibercept, ranibizumab (Lucentis) and bevacizumab (Avastin). Our results show that compounding and storage for one week does not compromise the functional activity of the biologics and allows for safe and cost-effective compounding of anti-VEGF biologics for intravitreal injections in prefilled silicone oil-free syringes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41598-019-54226-7

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Eye with symptomatic silicone oil droplets and an anti-VEGF biologic after compounding. (a) Biomicroscopic picture of small silicone oil (SO) droplets in the upper anterior part of the vitreous body; the droplets appear as small clear spheres. Margo of upper eye lid (M). (b) Labelled plastic bag containing a prefilled, silicone oil-free plastic syringe attached to a capped needle. The images have been cropped.
Figure 1 Eye with symptomatic silicone oil droplets and an anti-VEGF biologic after compounding. (a) Biomicroscopic picture of small silicone oil (SO) droplets in the upper anterior part of the vitreous body; the droplets appear as small clear spheres. Margo of upper eye lid (M). (b) Labelled plastic bag containing a prefilled, silicone oil-free plastic syringe attached to a capped needle. The images have been cropped.CC BY · PubMed Central
Figure 2 Concentrations of the three anti-VEGF biologics before and after storage in silicone oil-free plastic syringes. Undiluted and diluted (1:10) samples collected at day 0 (D0) shown in black, and day 7 (D7) shown in blue for (a) ranibizumab, (b) aflibercept and (c) bevacizumab. Measurements are presented as mean ± SD. For each sample set n = 6. The unpaired Student’s t-test was used for statistical analysis.
Figure 2 Concentrations of the three anti-VEGF biologics before and after storage in silicone oil-free plastic syringes. Undiluted and diluted (1:10) samples collected at day 0 (D0) shown in black, and day 7 (D7) shown in blue for (a) ranibizumab, (b) aflibercept and (c) bevacizumab. Measurements are presented as mean ± SD. For each sample set n = 6. The unpaired Student’s t-test was used for statistical analysis.CC BY · PubMed Central
Figure 3 SDS-PAGE analysis. Non-reducing and reducing SDS-PAGE analysis of (a,b) ranibizumab D0 (sample 1–6) and D7 (sample 7–12), (c,d) bevacizumab D0 (sample 1–6) and D7 (7–12), and (e,f) ranibizumab D0 (sample 1–6) and D7 (sample 7–12). The images have not been cropped.
Figure 3 SDS-PAGE analysis. Non-reducing and reducing SDS-PAGE analysis of (a,b) ranibizumab D0 (sample 1–6) and D7 (sample 7–12), (c,d) bevacizumab D0 (sample 1–6) and D7 (7–12), and (e,f) ranibizumab D0 (sample 1–6) and D7 (sample 7–12). The images have not been cropped.CC BY · PubMed Central
Figure 4 Schematic overview of three commercially available anti-VEGF biologics. Ranibizumab (a) is composed of the affinity maturated Fab of bevacizumab, (b) bevacizumab is a full-length IgG1 antibody and (c) aflibercept is composed of domains from VEGFR1 and 2 fused to an IgG1 Fc-region. The figure was created with BioRender software.
Figure 4 Schematic overview of three commercially available anti-VEGF biologics. Ranibizumab (a) is composed of the affinity maturated Fab of bevacizumab, (b) bevacizumab is a full-length IgG1 antibody and (c) aflibercept is composed of domains from VEGFR1 and 2 fused to an IgG1 Fc-region. The figure was created with BioRender software.CC BY · PubMed Central
Figure 5 SEC analysis. SEC elution profiles of (a) ranibizumab, (b) aflibercept, and (c) bevacizumab at D0 (black) and D7 (blue). Comparison of AUC (%) of peak A and B for samples of (d) aflibercept and (e) bevacizumab from D0 and D7. Ranibizumab (a) only displayed one peak. The data are presented as mean ± SD. For each sample set n = 6. The unpaired Student’s t-test was used for statistical analysis.
Figure 5 SEC analysis. SEC elution profiles of (a) ranibizumab, (b) aflibercept, and (c) bevacizumab at D0 (black) and D7 (blue). Comparison of AUC (%) of peak A and B for samples of (d) aflibercept and (e) bevacizumab from D0 and D7. Ranibizumab (a) only displayed one peak. The data are presented as mean ± SD. For each sample set n = 6. The unpaired Student’s t-test was used for statistical analysis.CC BY · PubMed Central
Figure 6 Thermal stability. Tm values for D0 (black) and D7 (blue) for (a) ranibizumab, (b) aflibercept and (c) bevacizumab. The melting process for (a) ranibizumab and (c) bevacizumab occurred in one event, whereas for (b) aflibercept, it occurred in three different temperature ranges. This was expected as aflibercept consists of three structurally different domains. The data are presented as mean ± SD. For each sample set n = 6, as measured in triplicates. The unpaired Student’s t-test was used for statistical analysis.
Figure 6 Thermal stability. Tm values for D0 (black) and D7 (blue) for (a) ranibizumab, (b) aflibercept and (c) bevacizumab. The melting process for (a) ranibizumab and (c) bevacizumab occurred in one event, whereas for (b) aflibercept, it occurred in three different temperature ranges. This was expected as aflibercept consists of three structurally different domains. The data are presented as mean ± SD. For each sample set n = 6, as measured in triplicates. The unpaired Student’s t-test was used for statistical analysis.CC BY · PubMed Central
Figure 7 Binding properties to VEGF. Binding to VEGF in ELISA for titrated amounts (1000–0.5 ng/mL) of (a) ranibizumab, (b) aflibercept, and (c) bevacizumab at D0 (black) and D7 (blue). Comparison of binding to VEGF at D0 and D7 for the following concentrations: ranibizumab 74 ng/mL (d) and 12.34 ng/mL for aflibercept (e) and bevacizumab (f). For each sample set n = 6. The unpaired Student’s t-test was used for statistical analysis.
Figure 7 Binding properties to VEGF. Binding to VEGF in ELISA for titrated amounts (1000–0.5 ng/mL) of (a) ranibizumab, (b) aflibercept, and (c) bevacizumab at D0 (black) and D7 (blue). Comparison of binding to VEGF at D0 and D7 for the following concentrations: ranibizumab 74 ng/mL (d) and 12.34 ng/mL for aflibercept (e) and bevacizumab (f). For each sample set n = 6. The unpaired Student’s t-test was used for statistical analysis.CC BY · PubMed Central
Figure 8 VEGF binding properties as measured by SPR. Sensorgrams showing the binding profiles to immobilized VEGF (~300 RU) for (a) ranibizumab (800 nM), (b) aflibercept (100 nM), and (c) bevacizumab (100 nM) at D0 (black dotted line) and D7 (blue). For each injection n = 6. The binding profiles (RU) have been normalized to baseline and the blank values subtracted.
Figure 8 VEGF binding properties as measured by SPR. Sensorgrams showing the binding profiles to immobilized VEGF (~300 RU) for (a) ranibizumab (800 nM), (b) aflibercept (100 nM), and (c) bevacizumab (100 nM) at D0 (black dotted line) and D7 (blue). For each injection n = 6. The binding profiles (RU) have been normalized to baseline and the blank values subtracted.CC BY · PubMed Central
Figure 9 pH-dependent FcRn binding properties. Binding to a constant amount of GST-tagged human FcRn (1 µg/mL) at pH 5.5 and pH 7.2 for titrated amounts (1000–0.5 ng/mL) of (a) aflibercept and (b) bevacizumab at D0 (black and dark green) and D7 (blue and light green). Comparison of binding to human FcRn at D0 (black) and D7 (blue) at a given concentration of 111 ng/mL aflibercept (c) and bevacizumab (d). For each sample set n = 6. The unpaired Student’s t-test was used for statistical analysis.
Figure 9 pH-dependent FcRn binding properties. Binding to a constant amount of GST-tagged human FcRn (1 µg/mL) at pH 5.5 and pH 7.2 for titrated amounts (1000–0.5 ng/mL) of (a) aflibercept and (b) bevacizumab at D0 (black and dark green) and D7 (blue and light green). Comparison of binding to human FcRn at D0 (black) and D7 (blue) at a given concentration of 111 ng/mL aflibercept (c) and bevacizumab (d). For each sample set n = 6. The unpaired Student’s t-test was used for statistical analysis.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 43 references

Cited by

See all 48

Metadata

Authors
Lode, H. E., Gjølberg, T. T., Foss, S., Sivertsen, M. S., Brustugun, J., Andersson, Y., Jørstad, Ø. K., Moe, M. C., & Andersen, J. T.
Affiliations
Oslo University Hospital (NO)
Corresponding author
  • Moe, Morten Carstens
  • Andersen, Jan Terje
Venue
Scientific Reports
Published
2019-12-02
Volume
9
Issue
1
Pages
18021-18021
ISSN
2045-2322 (ISSN-L)
OpenAlex
W2989847831
Cited by
40
References
43
Citations by year
2026: 5 · 2025: 6 · 2024: 3 · 2023: 6 · 2022: 7 · 2021: 8 · 2020: 5
FWCI
4.91
Type
journal article
Language
en
Open access
Licence
Locations
  • Scientific Reports (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • NORA - Norwegian Open Research Archives (submittedVersion, cc-by)
Funders
  • Norges Forskningsråd (251037/F20, 179573, 287927)
  • Ministry of Health and Care Services | Helse Sør-Øst RHF (2018052)
Topics
  • Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
Keywords
pharmaceutical compounding, intravitreal injection, prefilled syringes, drug storage stability, aflibercept, ranibizumab, bevacizumab, neovascular age-related macular degeneration, diabetic macular edema, drug repackaging
MeSH terms
Biological Products, Chemistry, Pharmaceutical, Diabetic Retinopathy, Drug Compounding, Drug Stability, Drug Storage, Humans, Macular Degeneration, Macular Edema, Oxidation-Reduction, Plastics, Silicone Oils, Syringes, Angiogenesis Inhibitors, Vascular Endothelial Growth Factor A, Intravitreal Injections

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A new method for pharmaceutical compounding and storage of anti-VEGF biologics for intravitreal use in silicone oil-free prefilled plastic syringes. https://app.cochat.ai/papers/10.1038/s41598-019-54226-7
The paper
Lode, H. E., Gjølberg, T. T., Foss, S., Sivertsen, M. S., Brustugun, J., Andersson, Y., Jørstad, Ø. K., Moe, M. C., & Andersen, J. T. (2019). A new method for pharmaceutical compounding and storage of anti-VEGF biologics for intravitreal use in silicone oil-free prefilled plastic syringes. Scientific Reports. https://doi.org/10.1038/s41598-019-54226-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.